/term/cash-receipts-from-deposits-by-banks-and-customers/OSTO:IRLAB%20A IRLAB Therapeutics AB (OSTO:IRLAB A) Cash Receipts from Dep
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Cash Receipts from Deposits by Banks and Customers

IRLAB Therapeutics AB (OSTO:IRLAB A) Cash Receipts from Deposits by Banks and Customers


View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB Cash Receipts from Deposits by Banks and Customers?

Cash Receipts from Deposits by Banks and Customers only applicable to companies reporting Cash Flow from Operations in direct method.

IRLAB Therapeutics AB (OSTO:IRLAB A) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Cash Receipts from Deposits by Banks and Customers
Comparable Companies
OSTO:IMMU OSTO:NICA OSTO:SANION OSTO:GUARD OSTO:MVIR OSTO:KDEV OSTO:KAN OSTO:INDEX OSTO:IVACC OSTO:CLBIO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
6IRA:Germany
Address
Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
Website
https://www.irlab.se
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.